Clinical Trial Update: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a quadruplet regimen (carfilzomib, lenalidomide, dexamethasone, and elotuzumab) in relapsed/refractory multiple myeloma; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-07-26